Learn how dosing escalations trigger longer monitoring for reactions in a phase 2 trial of subcutaneous blinatumomab in MPAL, then shorten in later cycles as safety and protocols allow.
Ashkan Emadi, MD, PhD
Articles by Ashkan Emadi, MD, PhD
Early trial shows subcutaneous blinatumomab drives remission in rare MPAL, enabling simpler community care and wider access.